Share This Author
In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis.
- W. Yew, S. Kwan, W. K. Ma, M. Khin, P. Chau
- Medicine, BiologyThe Journal of antimicrobial chemotherapy
- 1 August 1990
Favourable MICs of ofloxacin were demonstrated for 147 isolates of Mycobacterium tuberculosis, indicating more rapid bacteriolysis and implying the definite efficacy of of loxacIn when used together with second-line accompanying drugs in the management of resistant tuberculosis.
The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis.
Combination of ofloxacin and amikacin in the treatment of sternotomy wound infection.
Preliminary results from a future prospective study with ofloxacin as single agent for soft tissue, particularly postoperative sepsis due to M fortuitum, will be planned are encouraged by these preliminary results.
Single daily-dose ofloxacin monotherapy for Mycobacterium fortuitum sternotomy infection.
Monotherapy with ofloxacin is recommended for M fortuitum infection of wound and soft tissue, with in vitro susceptibility studies as a guide, pending further reinforcing clinical evidence.
Ofloxacin therapy of Mycobacterium fortuitum infection: further experience.
Four methods for determining albumin in azotemic sera evaluated.
Four methods used to measure albumin concentration in sera of patients with various degrees of renal failure are evaluated, comparing results with those by the most specific method, radial immunodiffusion.
Minimal bactericidal and inhibitory concentrations of ofloxacin on Mycobacterium fortuitum at pH 7 and 5: therapeutic implications.
Antimicrobial activity of ofloxacin and other agents against mycobacterial isolates from postoperative sternotomy wounds.
Investigation of median sternotomy wound infections from Mycobacterium fortuitum and M chelonei in a cardiothoracic hospital in 1987 and 1988 indicates that ofloxacin alone is as effective as the combination of oflOxacin and amikacin in treating M fortuitsum, but not M che lonei, infection.